This activity, presented by Dr. Marc A. Riedl, highlights recently updated HAE clinical practice guidelines, treatment advances, and emerging therapies for HAE. Dr. Riedl discusses how to distinguish CVID from other immunodeficiencies as well as immunoglobulin replacement therapy and emerging targeted therapies for CVID. Learners will gain insight on optimizing individualized patient care and considerations for improving quality of life for patients with HAE and CVID.
Upon completion of this activity, participants should be better able to:
Professor of Medicine
Clinical Director, US HAEA Angioedema Center
Clinical Service Chief & Training Program Director
Division of Rheumatology, Allergy & Immunology
University of California, San Diego
San Diego, CA
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources